# 1 **M-DATA: A Statistical Approach to Jointly Analyzing** *De Novo*

# 2 **Mutations for Multiple Traits**



### 26 **Abstract**

27 Recent studies have demonstrated that multiple early-onset diseases have shared risk genes, 28 based on findings from *de novo* mutations (DNMs). Therefore, we may leverage information 29 from one trait to improve statistical power to identify genes for another trait. However, there are 30 few methods that can jointly analyze DNMs from multiple traits. In this study, we develop a 31 framework called M-DATA (**M**ulti-trait framework for *De novo* mutation **A**ssociation **T**est with 32 **A**nnotations) to increase the statistical power of association analysis by integrating data from 33 multiple correlated traits and their functional annotations. Using the number of DNMs from 34 multiple diseases, we develop a method based on an Expectation-Maximization algorithm to 35 both infer the degree of association between two diseases as well as to estimate the gene 36 association probability for each disease. We apply our method to a case study of jointly 37 analyzing data from congenital heart disease (CHD) and autism. Our method was able to 38 identify 23 genes for CHD from joint analysis, including 12 novel genes, which is substantially 39 more than single-trait analysis, leading to novel insights into CHD disease etiology.

40

### 41 **Author Summary**

42 Congenital heart disease (CHD) is the most common birth defect. With the development of new 43 generation sequencing technology, germline mutations such as *de novo* mutations (DNMs) with 44 deleterious effects can be identified to aid in discovering the genetic causes for early on-set 45 diseases such as CHD. However, the statistical power is still limited by the small sample size of 46 DNM studies due to the high cost of recruiting and sequencing samples, and the low occurrence 47 of DNMs given its rarity. Compared to DNM analysis for other diseases, it is even more 48 challenging for CHD given its genetic heterogeneity. Recent research has suggested shared 49 disease mechanisms between early-onset neurodevelopmental diseases and CHD based on

2 and 2 and 2 and 2 and 2 and 2



# 73 **Introduction**

74 Congenital heart disease (CHD) is the most common birth defect. It affects 0.8% of live birth 75 and accounts for one-third of all major congenital abnormalities [1, 2]. CHD is associated with 76 both genetic and environmental factors [2]. It is genetically heterogenous and the estimated 77 heritability in a Danish twin study is close to 0.5 [3].

78

79 Studies on *de novo* mutations (DNMs) have been successful in identifying risk genes for early 80 on-set diseases as DNMs with deleterious effects have not been through natural selection. By 81 conducting whole-exome sequencing (WES) studies for parent-offspring trios, there are 82 cumulative findings of potential risk genes for CHD and neurodevelopmental disorders by 83 identifying genes with more DNMs than expected by chance [4-6]. However, the statistical 84 power for identifying risk genes is still hampered by the limited sample size of WES due to its 85 relatively high cost in recruiting and sequencing samples, as well as the low occurrence of 86 DNMs given its rarity.

87

88 Meta-analysis and joint analysis are two major approaches to improve the statistical power by 89 integrating information from different studies. Meta-analysis studies on WES DNMs and 90 Genome-wide Association Studies (GWAS) for multiple traits have been conducted [7, 8]. 91 However, these approaches may overlook the heterogeneity among traits, thus hinder the ability 92 to interpret finding for each single trait. By identifying the intersection of top genes from multiple 93 traits, some recent studies have shown that there are shared risk genes between CHD and 94 autism [9, 10]. Shared disease mechanism for early-onset neurodevelopmental diseases has 95 also been reported [11, 12]. Based on these findings, joint analysis methods have been 96 proposed and gained success in GWAS and expression quantitative trait loci (eQTL) studies. 97 Studies have shown that multi-trait analysis can improve statistical power [13-19] and accuracy

98 of genetic risk prediction [20-22]. Currently, there lacks joint analysis methods to analyze DNM 99 data on multiple traits globally, with the exception of mTADA [23].

100

101 In addition to joint analysis, integrating functional annotations has also been shown to improve 102 statistical power in GWAS [15, 24] and facilitate the analysis of sequencing studies [25] [26]. 103 There is a growing number of publicly available tools to annotate mutations in multiple 104 categories, such as the genomic conservation, epigenetic marks, protein functions and human 105 health. With these resources, there is a need to develop a statistical framework for jointly 106 analyzing traits with shared genetic architectures and integrating functional annotations for DNM 107 data.

108

109 In this article, we propose a **M**ulti-trait *De novo* mutation **A**ssociation **T**est with **A**nnotations, 110 named M-DATA, to identify risk genes for multiple traits simultaneously based on pleiotropy and 111 functional annotations. We demonstrate the performance of M-DATA through extensive 112 simulation studies and real data examples. Through simulations, we illustrate that M-DATA is 113 able to accurately estimate the proportion of disease-causing genes between two traits under 114 various genetic architectures. M-DATA outperformed single-trait approaches and methods even 115 if annotation information was not used. Annotations can further boost the power of M-DATA. We 116 applied M-TADA to identify risk genes for CHD and autism. There are 23 genes discovered to 117 be significant for CHD, including 12 novel genes, bringing novel insight to the disease etiology 118 of CHD.

119

120

121

122

 $5<sub>5</sub>$ 

### 123 **Methods**

#### 124 *Probabilistic model*

- 125 First, we consider the simplest case with only one trait, and then we extend our model to
- 126 multiple traits. We denote  $Y_i$  as the DNM count for gene i in a case cohort, and assume  $Y_i$  come
- 127 from the mixture of null  $(H_0)$ , and non-null  $(H_1)$ , with proportion  $\pi_0 = 1 \pi$  and  $\pi_1 = \pi$
- 128 respectively. Let  $Z_i$  be the latent binary variable indicating whether this gene is associated with
- 129 the trait of interest, where  $Z_i = 0$  means gene i is unassociated  $(H_0)$ , and  $Z_i = 1$  means gene i
- 130 is associated  $(H_1)$ . Then, we have the following model:

$$
Z_i \sim Bernoulli(\pi)
$$
  

$$
Y_i | Z_i = 0 \sim Poisson(2N\mu_i)
$$
  

$$
Y_i | Z_i = 1 \sim Poisson(2N\mu_i \gamma_i)
$$

131 where N is the sample size of the case cohort,  $\mu_i$  is the mutability of gene i estimated using the 132 framework in Samocha, Robinson (27), and  $y_i$  is the relative risk of the DNMs in the risk gene 133 and is assumed to be larger than 1. The derivation of the parameter of the Poisson distribution 134 is the same as that in TADA [6, 28]. We define this model as the single-trait model without 135 annotation in our main text.

136

137 To leverage information from functional annotations, we use an exponential link between  $y_i$  and 138  $X_i$ ,

$$
Y_i = exp(X_i^T \beta),
$$

139 where  $X_i^T$  is the transpose of the functional annotation vector of gene i, and  $\beta$  is the effect size 140 vector of the functional annotations. Under the assumption that risk genes have higher burden 141 than non-risk genes, we expect the estimated value of  $\gamma_i$  to be larger than 1.

143 Now we extend our model to consider multiple traits simultaneously. To unclutter our notations, 144 we present the model for the two-trait case. Suppose we have gene counts  $Y_{i1}$  and  $Y_{i2}$  for gene <sup>145</sup> $i$  from two cohorts with different traits. Similarly, we introduce latent variables 146  $Z_i = [Z_{i00}, Z_{i10}, Z_{i01}, Z_{i11}]$  to indicate whether gene i is associated with the traits. Specifically, <sup>147</sup>- $_0 = 1$  means the gene *i* is associated with neither trait,  $Z_{i10} = 1$  means that it is only 148 associated with the first trait,  $Z_{i01} = 1$  means that it is only associated with the second trait, and 149  $Z_{i11} = 1$  means that it is associated with both traits. Then, we have: 150  $Z_i \sim Multinomial(1, \pi)$ , with  $\pi = (\pi_{00}, \pi_{10}, \pi_{01}, \pi_{11})$ **151**  $\pi_{00} = \Pr(Z_{i00} = 1), Y_{i1} | Z_{i00} \sim Poisson(2N_1 \mu_i), Y_{i2} | Z_{i00} \sim Poisson(2N_2 \mu_i)$ **152**  $\pi_{10} = \Pr(Z_{i10} = 1), Y_{i1} | Z_{i10} \sim Poisson(2N_1 \mu_i \gamma_{i1}), Y_{i2} | Z_{i10} \sim Poisson(2N_2 \mu_i)$ **153**  $\pi_{01} = \Pr(Z_{i01} = 1), Y_{i1} | Z_{i01} \sim Poisson(2N_1\mu_i), Y_{i2} | Z_{i01} \sim Poisson(2N_2\mu_iY_{i2})$ **154**  $\pi_{11} = Pr(Z_{i11} = 1), Y_{i1}|Z_{i11} \sim Poisson(2N_1\mu_i\gamma_{i1}), Y_{i2}|Z_{i11} \sim Poisson(2N_2\mu_i\gamma_{i2})$ 155  $\gamma_{i1} = \exp(X_{i1}^T \beta_1), \gamma_{i2} = \exp(X_{i2}^T \beta_2)$ 156 where  $\pi$  is the corresponding risk proportion of genes belonging to each class, with 157  $\sum_{l \in \{00, 10, 01, 11\}} \pi_l = 1$ . Then, the risk proportion of the first trait and second trait is  $\pi_{10} + \pi_{11}$  and 158  $\pi_{01} + \pi_{11}$ , respectively. When there is no pleiotropy of the two traits,  $\pi_{11} = (\pi_{10} + \pi_{11})(\pi_{01} + \pi_{12})$ 159  $\pi_{11}$ ). The difference between  $\pi_{11}$  and  $(\pi_{10} + \pi_{11})(\pi_{01} + \pi_{11})$  reflects the magnitude of global 160 pleiotropy between the two traits.  $\mu_i$  is the same as our one-trait model.  $N_1$ ,  $\gamma_{i1}$  and  $X_{i1}$  are the 161 case cohort size, relative risk and annotation vector of gene *i* for the first trait.  $N_2$ ,  $\gamma_{i2}$  and  $X_{i2}$  are 162 similarly defined for the second trait.

163

164 Denote  $\theta = (\pi, \beta_1, \beta_2)$  the parameters to be estimated in our model. As we only consider *de* 165 *novo* mutations, they can be treated as independent as they occur with very low frequency. The 166 full likelihood function can be written as

$$
L(\theta) = \prod_{i=1}^{M} \sum_{l \in \{00, 10, 01, 11\}} [\pi_l \Pr(Y_{i1}, Y_{i2} | Z_{il} = 1; \theta)]^{Z_{il}}
$$

167 where M is the number of genes. The log-likelihood funciton is

$$
l(\theta) = \sum_{i=1}^{M} \log \sum_{l \in \{00, 10, 01, 11\}} [\pi_l \Pr(Y_{i1}, Y_{i2} | Z_{il} = 1; \theta)]^{Z_{il}}.
$$

168

#### 169 *Estimation*

170 Parameters of our models can be estimated using the Expectation-Maximization (EM) algorithm

171 [32]. It is very computationally efficient for our model without annotation because we have

172 explicit solutions for the estimation of all parameters in the M-step.

173

174 By Jenson's inequality, the lower bound  $Q(\Theta)$  of the log-likelihood function is  $\frac{M}{\sqrt{2\pi}}$ 

$$
l(\theta) \ge Q(\theta) = \sum_{i=1}^{M} \sum_{l \in \{00,10,01,11\}} [Z_{il}[\log(\pi_l) + \log(\Pr(Y_{i1}, Y_{i2} | Z_{il} = 1; \theta))]]
$$

175

176 The algorithm has two steps. In the E-step, we update the estimation of latent variables -178 That is, <sup>177</sup> $Z_{il}$ ,  $l \in \{00,01,10,11\}$  by its posterior probability under the current parameter estimates in round s.

$$
Z_{il}^{(s)} = \Pr(Z_{il} = 1 | Y_{i1}, Y_{i2}; \Theta^{(s)}) = \frac{\Pr(Z_{il} = 1, Y_{i1}, Y_{i2} | \Theta^{(s)})}{\Pr(Y_i | \Theta^{(s)})}
$$

$$
= \frac{\Pr(Z_{il} = 1 | \Theta^{(s)}) \Pr(Y_{i1}, Y_{i2} | Z_{il} = 1; \Theta^{(s)})}{\sum_{l' \in \{00, 01, 10, 11\}} \left[ \Pr(Z_{il'} = 1 | \Theta^{(s)}) \Pr(Y_{i1}, Y_{i2} | Z_{il'} = 1; \Theta^{(s)}) \right]}
$$

179

180 In the M-step, we update the parameters in  $\theta$  based on the estimation of  $Z_{il}$  in the E-step by<br>181 In maximizing  $O(\theta)$ . For  $\pi$ , there is an analytical solution, which is

181 maximizing  $Q(\theta)$ . For  $\pi$ , there is an analytical solution, which is  $\theta$ 

$$
\pi_l^{(s+1)} = \frac{\sum_{i=1}^{M} Z_{il}^{(s)}}{M}
$$

182

183 For the rest of derivation, we take the estimation process for the first trait as an example. Taking

184 the first order derivative of  $Q(\Theta)$  with respect to  $\beta_1$  as 0, we have<br>185  $d_{\phi} Q(\Theta)^{(s)} = \sum_{l=1}^{M} (Z_{l+1} + Z_{l+1})(Y_{l+1}X_{l+1} - 2N_{l+1})$ 

185 
$$
d_{\beta_1} Q(\theta)^{(s)} = \sum_{i=1}^{M} (Z_{i10} + Z_{i11}) (Y_{i1} X_{i1} - 2N_1 \mu_i \exp(X_{i1}^T \beta_1) X_{i1}) = 0.
$$

186

187 If we do not add any functional annotations to our model ( $X_{i1}$  degenerates to 1 and  $\beta_1$ <br>188 degenerates to a scalar), there exists an analytical solution for  $\beta_1$ .

188 degenerates to a scalar), there exists an analytical solution for  $\beta_1$ .

$$
\beta_1^{(s+1)} = \log \frac{\sum_{i=1}^{M} Y_{i1}(Z_{i10} + Z_{i11})}{\sum_{i=1}^{M} 2N_1\mu_i(Z_{i10} + Z_{i11})}
$$

189

However, there is no explicit solution for  $\beta_1$ , so we adopt the Newton-Raphson method for<br>191 estimation after adding functional annotations into our model. The second-order derivative 191 estimation after adding functional annotations into our model. The second-order derivatives for 192  $Q(\theta)$  is

$$
d_{\beta_1}^2 Q(\theta) = -\sum_{i=1}^M (Z_{i10} + Z_{i11}) (2N_1 \mu_i \exp(X_{i1}^T \beta_1) X_{i1} X_{i1}^T),
$$

193 Then, the estimate of  $\beta_1$  can be obtained as

$$
\beta_1^{(s+1)} = \beta_1^{(s)} - \left[d_{\beta_1}^2 Q(\Theta)^{(s)}\right]^{-1} d_{\beta_1} Q(\Theta)^{(s)},
$$

194

### 195 *Functional Annotation and Feature Selection*

196 As we have discussed, there are multiple sources of functional annotations for DNMs. For gene-197 level annotations, we can directly plug into our gene-based model. For variant-level annotations, 198 it is important to collapse the variant-level information into gene-level without diluting useful 199 information. Simply pulling over variant-level annotations of all base pairs within a gene may not 200 be the best approach. To better understand the relationship, we calculate the likelihood ratio of

the DNM counts under  $H_1$  and  $H_0$ . Under  $H_1$ , for all positions t within a gene *i*, the DNM count<br>202  $Y_{it}$  follows the Poisson distribution with relative risk  $y_{it}$  and mutability  $\mu_{it}$ , then we have

-202  $Y_{it}$  follows the Poisson distribution with relative risk  $\gamma_{it}$  and mutability  $\mu_{it}$  , then we have<br> $P(Y_i|H_1) = \prod_t P(Y_{it}|H_1) = \prod_t Poisson(2Nu_{it}v_{it})$ 

$$
\frac{P(Y_i|H_1)}{P(Y_i|H_0)} = \frac{\prod_t P(Y_{it}|H_1)}{\prod_t P(Y_{it}|H_0)} = \frac{\prod_t Poisson(2N\mu_{it}Y_{it})}{\prod_t Poisson(2N\mu_{it})}
$$
  
*X<sub>it</sub>*). There is likely to be at most one mutation a

 $\overline{a}$ 203 where  $γ_{it} = exp(β_0 + β_1 X_{it})$ . There is likely to be at most one mutation at each position *t* due to <br>204 the low frequency of DNM. We can further simplify the above equation to

 $204$  the low frequency of DNM. We can further simplify the above equation to

$$
\frac{P(Y_i|H_1)}{P(Y_i|H_0)} = \frac{\prod_t \exp(\beta_0 + \beta_1 X_{it} I\{Y_{it} = 1\}) \exp(-2N\mu_{it} \exp(\beta_0 + \beta_1 X_{it}))}{\prod_t \exp(-2N\mu_{it})}
$$
  
=  $\exp\left(\sum_t (\beta_0 + \beta_1 X_{it} I\{Y_{it} = 1\}) \exp\left(\sum_t -2N\mu_{it} [\exp(\beta_0 + \beta_1 X_{it}) - 1]\right)\right)$ 

205

206 Assuming the variant-level effect size  $\beta_1$  is small, we can apply Taylor expansion to the second<br>207 term of the above equation, term of the above equation,

$$
\frac{P(Y_i|H_1)}{P(Y_i|H_0)} \approx \exp\left(\sum_{t} (\beta_0 + \beta_1 X_{it} I\{Y_{it} = 1\}) \exp\left(\sum_{t} -2N\mu_{it} [\exp(\beta_0)(1 + \beta_1 X_{it}) - 1]\right)\right).
$$

208

209 If we center the collapsed variant-level annotations, we can apply  $\sum_t X_i$ <br>210 equation and further simplifv it as  $\ddot{\phantom{0}}$  $= 0$  to the above 210 equation and further simplify it as

$$
\frac{P(Y_i|H_1)}{P(Y_i|H_0)} \approx \exp\left(\sum_{t} (\beta_0 + \beta_1 X_{it} I\{Y_{it} = 1\}) \exp\left(\sum_{t} -2N\mu_{it} [\exp(\beta_0) - 1]\right)\right)
$$

$$
= \exp\left(\beta_0' + \beta_1' \sum_{t} (X_{it} I\{Y_{it} = 1\}).
$$

211

212 The above approximation motivates us to aggregate variant-level annotations to gene-level 213 annotations by summing up all annotation values of the mutations within a gene after 214 preprocessing each variant-level annotation.

216 We used variant-level annotations from ANNOVAR [29] in our analysis. We define loss-of-217 function (LoF) as frameshift insertion/deletion, splice site alteration, stopgain and stoploss 218 predicated by ANNOVAR, and define deleterious missense variants (Dmis) predicted by 219 MetaSVM [30]. Specifically, we included four categories of features including variant-level 220 deleteriousness (PolyPhen (D), PolyPhen(P) [33], MPC [34], CADD [35], REVEL [36], and LoF), 221 variant-level allele frequencies (gnomAD\_exome and gnomAD\_genome [31]), variant-level 222 splicing scores (dbscSNV\_ADA\_score, dbscSNV\_RF\_score [37] and dpsi\_zscore [38]) and 223 gene conservation scores (pLI and mis z) downloaded from gnomAD v2.1.1 [31] in real data 224 analysis. To construct gene-level annotation scores, variant-level annotations were collapsed by 225 summing up values calculated from the mutation information for each gene. All continuous 226 gene-level features were normalized before model fitting.

227

228 Before performing multi-trait analysis, features were selected separately for each trait by single-229 trait analysis. For each trait, all gene-level features were evaluated by Pearson's correlation. If 230 the Pearson's correlation between two annotations was larger than 0.7, only one annotation was 231 kept. After model fitting, we kept annotations with the absolute values of effect sizes larger than 232 0.01 and refit the model with the selected annotations. For multi-trait analyses, we constructed 233 the annotation matrices using the features selected from each trait (see more details in the S1 234 Text.)

235

#### 236 *Hypothesis Testing*

237 Without loss of generality, we take the first trait as an example to illustrate our testing procedure. 238 After we estimate the parameters, genes can be prioritized based on their joint local false 239 discovery rate (Jlfdr) [39]. For joint analysis of two traits, the Jlfdr of whether gene  $i$  is<br>240 associated with the first trait is 240 associated with the first trait is

$$
\text{Jlfdr}_1(Y_{i1}, Y_{i2}) = Pr(Z_{i00} + Z_{i01} = 1 | Y_{i1}, Y_{i2})
$$
\n
$$
= \frac{\pi_{00} Pr(Y_{i1}, Y_{i2} | Z_{i00} = 1; \theta) + \pi_{01} Pr(Y_{i1}, Y_{i2} | Z_{i01} = 1; \theta)}{\sum_{l' \in \{00, 01, 10, 11\}} \left[\pi_{l'} Pr(Y_{i1}, Y_{i2} | Z_{i1'} = 1; \theta)\right]}
$$
\n
$$
= \frac{\pi_{00} Poisson(Y_{i1}, 2N_1\mu_i) Poisson(Y_{i2}, 2N_2\mu_i) + \pi_{01} Poisson(Y_{i1}, 2N_1\mu_i) Poisson(Y_{i2}, 2N_2\mu_iY_{i2})}{\sum_{l' \in \{00, 01, 10, 11\}} \left[\pi_{l'} Pr(Y_{i1}, Y_{i2} | Z_{i1'} = 1; \theta)\right]}
$$

241 where  $\gamma_{i1} = \exp(X_{i1}^{\prime} \beta_1)$  and  $\gamma_{i2} = \exp(X_{i2}^{\prime} \beta_2)$ . When there is no annotation, both  $\beta_1$  and  $\beta_2$ <br>242 decrede from vectors to single intersect volves. Then  $\mu$  and  $\mu$  shore the same values and  $\frac{1}{2}$   $\frac{1}{2}$   $\frac{1}{2}$   $\frac{1}{2}$   $\frac{1}{2}$ degrade from vectors to single intercept values. Then  $\gamma_{i1}$  and  $\gamma_{i2}$  share the same values  $\exp(\beta_1)$ <br>243 and  $\exp(\beta_1)$  across all gones. Same formula can be used to compute the ilfdr of each gone and  $\exp(\beta_2)$  across all genes. Same formula can be used to compute the Jlfdr of each gene.<br>244 The definition of the Jlfdr is the posterior probability of a null hypothesis being true, given the 244 The definition of the Jlfdr is the posterior probability of a null hypothesis being true, given the 245 observed DNM count vector  $(Y_1, Y_2)$ . If we consider the first trait, the corresponding null<br>246 hypothesis is the gene *i* associates with both traits or only associates with the second tra 246 hypothesis is the gene *i* associates with both traits or only associates with the second trait, i.e.,<br>247  $Z_{\text{res}} + Z_{\text{res}} = 1$  And the corresponding Jlfdr is Ufdr.  $(Y_{\text{res}} | Y_{\text{res}}) = \Pr(Z_{\text{res}} + Z_{\text{res}} = 1 | Y_{\text{res}} | Y_{\text{$ 247  $Z_{i00} + Z_{i01} = 1$ . And the corresponding Jlfdr is Jlfdr<sub>1</sub>(Y<sub>i1</sub>, Y<sub>i2</sub>) = Pr (Z<sub>i00</sub> + Z<sub>i01</sub> = 1|Y<sub>i1</sub>, Y<sub>i2</sub>). In<br>248 . Comparison, the pavalue is defined as the probability of observing more extreme results given 248 comparison, the *p*-value is defined as the probability of observing more extreme results given 149 — the null hypothesis being true, i.e., *p*-value= Pr (More extreme than  $(Y_{i1}, Y_{i2})|Z_i$ <br>250 — compute it, we need to firstly define a partial order for comparing two-dimensi  $\sim$  250 compute it, we need to firstly define a partial order for comparing two-dimensional vector  $(Y_1, Y_2)$ ,<br>251 with which the genes associate with the first trait can stand out. One way to define the partial  $\frac{1}{2}$ = 1). To<br>or  $(Y_1, Y_2)$ 251 with which the genes associate with the first trait can stand out. One way to define the partial 252 order is to summarize the vector into a one-dimensional test statistic. Since this is not our focus, we will not discuss how to derive a new test statistic in the article. Although the Jlfdr<sub>1</sub> already<br>254 informs the probability of whether the gene is associated with the first trait, we should not informs the probability of whether the gene is associated with the first trait, we should not 255 directly use it as the p-value to infer the association status due to their different definitions and 256 properties.

257

258 The following relationship between Jlfdr and false discovery rates (Fdr) was shown in Jiang and 259 Yu (39),

260 
$$
Fdr_1(\mathcal{R}) = E\Big(\text{Jlfdr}_1(Y_1, Y_2) \Big| (Y_1, Y_2) \in \mathcal{R}\Big) \approx \frac{1}{|\{(Y_{i1}, Y_{i2}) \in \mathcal{R}\}|} \sum_{(Y_{i1}, Y_{i2}) \in \mathcal{R}} \text{Jlfdr}_1(Y_{i1}, Y_{i2}),
$$

261 where the rejection region is the set of two-dimensional vector  $(Y_1, Y_2)$  such that the null<br>262 hypothesis can be rejected based on a specific rejection criterion. For example, we can s hypothesis can be rejected based on a specific rejection criterion. For example, we can specify 263 a rejection criterion to select genes with large values of the weighted average DNM 264 counts: $0.9Y_1 + 0.1Y_2 \ge 5$ , then the corresponding rejection region is the upper right region above<br>265 the line of  $0.9Y_1 + 0.1Y_2 = 5$ . Here we omit the gene indicator *i* since the rejection region is 265 the line of  $0.9Y_1 + 0.1Y_2 = 5$ . Here we omit the gene indicator *i* since the rejection region is<br>266 defined on DNM count pairs of two traits regardless of the exact gene labels. Jiang and Yu 266 defined on DNM count pairs of two traits regardless of the exact gene labels. Jiang and Yu (56) 267 showed that the most powerful rejection region for a given Fdr level q is {JIfdr<sub>1</sub> $(Y_1, Y_2) \le t(q)$ }.<br>268 To determine the threshold  $t(a)$ , we sert the calculated lifdr. value of each gene in an 268 To determine the threshold  $t(q)$ , we sort the calculated Jlfdr $_1$ value of each gene in an<br>269 ascending order first. Denote the a-th IIfdr.value as IIfdr<sup>a</sup>. We can approximate the F 269 ascending order first. Denote the a-th Jlfdr<sub>1</sub> value as Jlfdr<sup>a</sup>. We can approximate the Fdr of the<br>270 region  $R = \{(Y, Y_2) | \text{U}fdr (Y_1, Y_2) \leq \text{U}fdr^3\}$  as 270 region  $\mathcal{R}_a = \{ (Y_1, Y_2) | \text{Jlfdr}_1 (Y_{i1}, Y_{i2}) \leq \text{Jlfdr}_1^a \}$  as

$$
\text{Fdr}\left(\mathcal{R}_a\right) = \frac{1}{a} \sum_{b=1}^a \text{Jlfdr}_1^b
$$

271 Denote  $c = \max \{a | \text{Fdr} (\mathcal{R}_a) \leq q\}$ , and then the threshold  $t(q)$  for Jlfdr<sub>1</sub> is Jlfdr<sup>c</sup><sub>1</sub>. For testing<br>272 association with the first trait, we reject all genes with Ilfdr. (Y<sub>i4</sub>, Y<sub>i2</sub>) < *t(a*). For both simu  $\frac{1}{x}$  fion with the first 272 association with the first trait, we reject all genes with Jlfdr $_1$ (Y $_{\rm i1}$ ,Y $_{\rm i2})$   $\leq$   $t(q)$ . For both simulation<br>273 and real data analyses, the global Fdr is controlled at  $a=0.05$ . The global Fdr is abb 273 and real data analyses, the global Fdr is controlled at  $q = 0.05$ . The global Fdr is abbreviated as<br>274 FDR in the following text. 274 FDR in the following text.

275

### 276 *Implementation of mTADA*

277 We used extTADA [11] to estimate the hyperpriors input for mTADA. For simulation and real 278 data application, we applied 2 MCMC chains and 10,000 iterations as recommended by the 279 authors [23]. We applied PP>0.8 as the threshold for risk gene inference. We benchmarked the 280 computational time of mTADA and M-DATA on Intel Xon Gold 6240 processors (2.6GHZ).- 281

#### 282 **Misspecified Model**

283 We tested if M-DATA have proper power when functional annotations affect the latent variables .<br>th 284  $Z_{il}$ ,  $l \in \{00, 01, 10, 11\}$  rather than the relative risk parameters  $\gamma_{i1}$  and  $\gamma_{i2}$ . Further, we assumed<br>285 that the latent variable  $Z_{i4.2}$  is associated with the functional annotation vector  $X_{i4.$ that the latent variable - is associated with the functional annotation vector -- 285 , which is the 286  $-$  functional annotation vector for gene  $i$  of the first trait,  $Z_{i01}$  is associated with  $X_{i2}$ , which is the<br>287  $-$  functional annotation vector for gene  $i$  of the second trait, and  $Z_{i44}$  is associated wit 287 functional annotation vector for gene  $i$  of the second trait, and  $Z_{i11}$  is associated with both  $X_i$ <br>288 and  $X_{i2}$  through the following forms:  $\overline{1}$ 288 and  $X_{i2}$  through the following forms:<br>

$$
P(Z_{i00}) = \frac{1}{1 + \exp(X_{i1}^T \beta_1) + \exp(X_{i2}^T \beta_2) + \exp(X_{i1}^T \beta_1 + X_{i2}^T \beta_2)}
$$
  
\n
$$
P(Z_{i10}) = \frac{\exp(X_{i1}^T \beta_1)}{1 + \exp(X_{i1}^T \beta_1) + \exp(X_{i2}^T \beta_2) + \exp(X_{i1}^T \beta_1 + X_{i2}^T \beta_2)}
$$
  
\n
$$
P(Z_{i01}) = \frac{\exp(X_{i2}^T \beta_2)}{1 + \exp(X_{i1}^T \beta_1) + \exp(X_{i2}^T \beta_2) + \exp(X_{i1}^T \beta_1 + X_{i2}^T \beta_2)}
$$
  
\n
$$
P(Z_{i11}) = \frac{\exp(X_{i1}^T \beta_1 + X_{i2}^T \beta_2)}{1 + \exp(X_{i1}^T \beta_1) + \exp(X_{i2}^T \beta_2) + \exp(X_{i1}^T \beta_1 + X_{i2}^T \beta_2)}
$$
  
\n
$$
\pi_{11} = \Pr(Z_{i11} = 1) \quad Y_{i1} | Z_{i21} \approx Poisson(2N, 11) \quad Y_{i2} | Z_{i21} \approx Poisson(2N, 11) \quad Y_{i1} | Z_{i21} \approx Poisson(2N, 11) \quad Y_{i21} | Z_{i11} \approx Poisson(2N, 11) \quad Y_{i21} | Z_{i21} \approx Poisson(2N, 11) \quad Y_{i1} | Z_{i21} \approx Poisson(2N, 11) \quad Y_{i21} | Z_{i11} \approx Poisson(2N, 11) \quad Y_{i1} | Z_{i21} \approx Poisson(2N, 11) \quad Y_{i1} | Z_{i21} \approx Poisson(2N, 11) \quad Y_{i21} | Z_{i11} \approx Poisson(2N, 11) \quad Y_{i1} | Z_{i21} \approx Poisson(2N, 11) \quad Y_{i1} | Z_{i21} \approx Poisson(2N, 11) \quad Y_{i21} | Z_{i11} \approx Poisson(2N, 11) \quad Y_{i21} | Z_{i11} \approx Poisson(2N
$$

289 
$$
\pi_{00} = \Pr(Z_{i00} = 1), Y_{i1} | Z_{i00} \sim Poisson(2N_1\mu_i), Y_{i2} | Z_{i00} \sim Poisson(2N_2\mu_i)
$$
  
290 
$$
\pi_{i0} = \Pr(Z_{i00} = 1), Y_{i1} | Z_{i00} \sim Poisson(2N_1\mu_i), Y_{i2} | Z_{i00} \sim Poisson(2N_2\mu_i)
$$

290 
$$
\pi_{10} = Pr(Z_{i10} = 1), Y_{i1} | Z_{i10} \sim Poisson(2N_1 \mu_i Y_{i1}), Y_{i2} | Z_{i10} \sim Poisson(2N_2 \mu_i)
$$
  
291 
$$
\pi_{2i} = Pr(Z_{i2i} = 1) Y_{i2} | Z_{i2i} \sim Poisson(2N_2 \mu_i) Y_{i2} | Z_{i2i} \sim Poisson(2N_2 \mu_i)
$$

291 
$$
\pi_{01} = Pr(Z_{i01} = 1), Y_{i1} | Z_{i01} \sim Poisson(2N_1 \mu_i), Y_{i2} | Z_{i01} \sim Poisson(2N_2 \mu_i Y_{i2})
$$
  
292 
$$
\pi_{ii} = Pr(Z_{ii1} = 1), Y_{ii} | Z_{ii2} \sim Poisson(2N_1 \mu_i), Y_{i2} | Z_{ii3} \sim Poisson(2N_2 \mu_i Y_{i2})
$$

292 
$$
\pi_{11} = Pr(Z_{i11} = 1), Y_{i1}|Z_{i11} \sim Poisson(2N_1\mu_iY_{i1}), Y_{i2}|Z_{i11} \sim Poisson(2N_2\mu_iY_{i2}),
$$
  
293 where π is the corresponding risk proportion of genes belonging to each class, with

 $\pi$  is the corresponding risk proportion of genes belonging to each class, with<br> $\pi$  and  $\pi$ ,  $\pi$  = 1. Here,  $\mu_i$  is the mutability of gene i.  $N_i$ ,  $\nu_{i1}$  and  $X_{i2}$  are the case

294  $\sum_{l \in \{00, 10, 01, 11\}} \pi_l = 1$ . Here,  $\mu_i$  is the mutability of gene  $i$ .  $N_1$ ,  $\gamma_{i1}$  and  $X_{i1}$  are the case cohort size,<br>295 relative risk and annotation vector of gene  $i$  for the first trait. Similar

 $\frac{295}{296}$  relative risk and annotation vector of gene *i* for the first trait. Similarly,  $N_2$ ,  $\gamma_{i2}$  and  $X_{i2}$  are defined for the second trait.

296 defined for the second trait.

297

### 298 **Verification and Comparison**

#### 299 *Estimation Evaluation*

300 We conducted comprehensive simulation studies to evaluate the estimation and power 301 performance of M-DATA. We set the total number of genes M to 10,000, where genes were 302 randomly selected from gnomAD v2.1 [31]. We set the size of the case cohort at 2000, 5000 303 and 10000, corresponding to a small, medium and large WES study. We assumed the 304 proportion of risk genes to be 0.1 for each trait (i.e.,  $\pi_{10} + \pi_{11} = \pi_{01} + \pi_{11} = 0.1$ ), and varied the<br>305 shared risk proportion  $\pi_{11}$  at 0.01, 0.03, 0.05, 0.07 and 0.09. When  $\pi_{11} = 0.01$ , it corresponds 305 shared risk proportion  $\pi_{11}$  at 0.01, 0.03, 0.05, 0.07 and 0.09. When  $\pi_{11} = 0.01$ , it corresponds to 306 the absence of pleiotropy between two traits, and we expect our multi-trait models to perform the absence of pleiotropy between two traits, and we expect our multi-trait models to perform 307 similarly as our single-trait models.

308

309 We first evaluated the performance of estimation for our models, and then we conducted power 310 analysis for our single-trait models and multi-trait models. To evaluate the estimation 311 performance for multi-trait models, we simulated the true model with two Bernoulli annotations, 312 and set the parameter of the Bernoulli distributions to 0.5 for both traits. We varied the effect 313 sizes of annotations  $(\beta_{j0}, \beta_{j1}, \beta_{j2})$ ,  $j = 1,2$  from  $(3,0.1,0.1)$   $(3,0.1,0)$  and  $(3,0,0)$ , which<br>314 corresponds to the cases when both annotations are effective, only the first annotatio examples of annotations (p<sub>10</sub>, p<sub>11</sub>, p<sub>22</sub>, p<sub>211</sub>, p<sub>211</sub>, c<sub>21</sub>, p<sub>212</sub>, p<sub>212</sub>, p<sub>21</sub>, p<sub>21</sub>, p<sub>21</sub>, matrice,<br>314 corresponds to the cases when both annotations are effective, only the first annotation is 315 effective and no annotation is effective. We evaluated the estimates of shared proportion of risk 316 genes  $\pi_{11}$  and the risk gene proportion for a single trait. There are in total 27 simulation settings<br>317 for estimation evaluation. To obtain an empirical distribution of our estimated parameters, we for estimation evaluation. To obtain an empirical distribution of our estimated parameters, we 318 replicated the process for 50 times for each setting. We simulated the two traits in a symmetrical 319 way, so we only present the results of the first trait. The performance of estimation under the scenario that both annotations are effective+', +' <sup>320</sup> -0.1,0.1, Z 1,2 are shown in Fig 1. --321 The rest of scenarios are shown in Fig A in the S1 Text.

322





330

323

#### 331 *Power Evaluation*

332 Given that the effective number of functional annotations for DNM data in real world is unknown, 333 we explored the power performance of single-trait and multi-trait models when annotations are 334 only partially observed. We varied the effect size of annotations from from 335 and , which corresponds to the cases when effect of 336 annotations is weak, moderate, and strong. We assumed that only the first two annotations can 337 be observed. We first demonstrated our model can control FDR (Fig B in the S1 Text) under 338 theses settings and then evaluated power (Fig 2), type I error (Fig C in the S1 Text), and AUC 339 (Fig D in the S1 Text) for our single-trait models and multi-trait models. There are in total 45

#### 340 simulation settings. Under each setting, the data were simulated based on our multi-trait model



### 341 with annotations (Methods).



343 **Fig 2. Power performance under different strengths of annotations.** The panels from top to bottom show the 344 power performance under weak, moderate and strong annotations, respectively. For each panel, each plot from left to 345 right represents study sample size of 2000, 5000, and 10000, respectively. Within each plot, boxes from left to right 346 represent the proportion of shared risk genes being 0.01, 0.03, 0.05, 0.07 and 0.09, respectively. Each scenario is 347 replicated for 50 times in our simulations.







366 **Fig 3. Comparisons of M-DATA and mTADA under different strengths of annotations.** The panels from top to 367 bottom show the power performance under weak, moderate and strong annotations, respectively. For each panel, 368 each plot from left to right represents study sample size of 2000, 5000, and 10000, respectively. Within each plot,

369 boxes from left to right represent the proportion of shared risk genes being 0.01, 0.03, 0.05, 0.07 and 0.09,

370 respectively. Each scenario is replicated for 50 times in our simulations.

371

### 372 **Robustness to Model Misspecification**

373 We also evaluated the power performance of M-DATA under misspecified models (Methods),

- 374 where we simulated two Bernoulli annotations that affect the latent variables
- <sup>375</sup> $Z_{i}$ ,  $l \in \{00, 10, 01, 11\}$ , and set the parameter of the Bernoulli distributions to 0.5 for both traits.
- .<br>س 376 We varied the effect sizes of annotations on the latent variables  $(\beta_{j0}, \beta_{j1}, \beta_{j2}), j = 1,2$  at (-<br>377 = 3.0.5.0.5), (-3.1.1) and (-3.1.5.1.5), which corresponds to the case when the effect of
- 377 3,0.5,0.5), (-3,1,1) and (-3,1.5,1.5), which corresponds to the case when the effect of
- 378 annotations is weak, moderate, and strong, respectively. The relative risk parameters  $\gamma_{i1}$  and<br>379  $\gamma_{i2}$  were set at 25. We simulated DNM counts under this misspecified model and evaluated th
- 379  $y_{i2}$  were set at 25. We simulated DNM counts under this misspecified model and evaluated the
- 7-380 performance of M-DATA multi-trait models for different sizes of DNM cohort (1000, 2000, and
- 381 4000). We observed that M-DATA can control FDR under all settings and the multi-trait model
- 382 with annotations had better power than the multi-trait model without annotation with the increase
- 383 of the effect size of annotations (Fig 4).

**(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.<br>It is made available under a CC-BY-NC-ND 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2021.05.22.21257421;](https://doi.org/10.1101/2021.05.22.21257421) this version posted September 7, 2021. The copyright holder for this preprint



384



386 power and FDR under weak, moderate and strong annotations on the latent variables

387 respectively. For each panel, each plot from left to right represents study sample size of 1000, 2000, and 4000,

388 respectively. Each scenario is replicated for 50 times in our simulations.

389

## 390 **Application**

- 391 We applied M-DATA to real DNM data from 2,645 CHD probands reported in Jin et al. [4] and
- 392 5,623 autism probands acquired from denovo-db [40]. We only considered damaging mutations
- 393 (LoF and Dmis) in our analysis as the number of non-deleterious mutations is not expected to
- 394 provide information to differentiate cases from controls biologically [41]. Details of functional

395 annotation and feature selection are included in Methods and S1 Text. In total, there were 396 18,856 genes tested by M-DATA.

397





415 annotations, the multi-trait model with annotations identified 6 additional genes, including

medRxiv preprint doi: [https://doi.org/10.1101/2021.05.22.21257421;](https://doi.org/10.1101/2021.05.22.21257421) this version posted September 7, 2021. The copyright holder for this preprint<br>(which was not certified by peer review) is the author/funder, who has grante

- 416 *CDK13*, *FRYL*, *LZTR1*, *NAA15*, *PTEN* and *RPL5*. There are two additional genes identified by
- 417 the single-trait model with annotations, but not the multi-trait models. Both of these two genes
- 418 did not have DNMs in autism and are around the margin of FDR threshold (0.05) for the multi-
- 419 trait model with annotations (*AHNAK* 0.056*, MYH6* 0.061).
- 420





422 **Fig 5. Venn diagram of identified genes in different models.** Compared to the single-trait model without 423 annotation, the single-trait model with annotations identified 4 additional genes. Compared to the multi-trait model 424 without annotation, the multi-trait model with annotations identified 5 additional genes. In total, the multi-trait models 425 identified 6 different genes compared to the single-trait models, including 4 novel human CHD genes (*CDK13*, *FRYL*, 426 *LZTR1* and *NAA15*).

427

428 To further illustrate the gain of power from multi-trait analysis, we visualized the posterior

- 429 probability of being shared risk gene for CHD and autism of identified genes in the multi-trait
- 430 model with annotations in Fig 6A (CHD) and Fig I in the S1 Text (autism). In the main text, we
- 431 further illustrate the results with the 23 significant CHD genes. All genes identified by the multi-

medRxiv preprint doi: [https://doi.org/10.1101/2021.05.22.21257421;](https://doi.org/10.1101/2021.05.22.21257421) this version posted September 7, 2021. The copyright holder for this preprint<br>(which was not certified by peer review) is the author/funder, who has grante

432 trait models are annotated with gene names, and the 6 additional genes identified by multi-trait 433 analyses are colored red. From this figure, we can see that most genes (5/6) have high 434 posterior probability of being shared. *RPL5* is at the margin of FDR threshold in the single-trait 435 models and may be prioritized in the multi-trait models by chance (Fig 6B). In addition, we 436 checked the correlation between the FDR of top genes identified by the multi-trait model with 437 annotations in the single-trait model with annotations (Fig 6B). All 6 genes have low FDR (<0.2) 438 in the single-trait model with annotations, which indicates multi-trait analysis can prioritize 439 marginal signals in single-trait analysis. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .<br>
Ited with gene names, and the 6 additional genes identified by multi-trait<br>
ad. From this figure, we can see that most genes (5/6) have high<br>
being shar





441 442 **Fig 6. Multi-trait analyses prioritized additional genes with high posterior probability of being shared risk**  443 **genes for CHD.** Gene names of the 23 genes identified by the multi-trait model with annotations are shown on the 444 plot and the additional 6 genes that were identified by the multi-trait models are marked in red. (A) shows that the 6 445 additional genes identified by the multi-trait models had high posterior probability of being shared. The x-axis 446 represents the posterior probability of being shared calculated from the multi-trait model with annotations. The y-axis 447 represents the FDR of genes calculated from the multi-trait model with annotations. (B) shows that the top genes in 448 the multi-trait model with annotations also had low FDR  $( $0.2$ )$  in the single-trait model with annotations. The x-axis 449 represents the FDR of genes calculated from the single-trait model with annotations. The y-axis represents the FDR 450 of genes calculated from the multi-trait model with annotations.

451 We take the 5 CHD genes identified by the multi-trait models, but not the single-trait models as 452 examples to demonstrate the pleiotropic effect. We selected the DNM counts of CHD and 453 autism, FDR of the single-trait model with annotations and FDR of the multi-trait model with 454 annotations model from the results (Table 2). From this table, we can see *CDK13, FRYL,*  455 *LZTR1, NAA15* and *PTEN* have 2 DNM counts for CHD and at least 1 shared DNM count with 456 autism. For *PTEN*, it has 4 shared counts with autism, and we can see a substantial increase of 457 significance in terms of FDR. Thus, the insight is that genes with shared counts with autism are 458 more likely to be prioritized for CHD in multi-trait analyses by leveraging the pleiotropic effect.



459 **Table 2. Pleiotropic effect boosts power for M-DATA multi-trait models.** 

460

461 Among the 23 identified genes from joint model with annotations, 11 were well established

462 known CHD genes based on a previously compiled gene list with 254 known CHD genes [4].

463 They are involved in essential developmental pathways or biological processes, such as Notch

464 signaling (*NOTCH1*), RAS signaling (*PTPN11*, *RAF1*, *SOS1*), PI3K/AKT signaling (*PTEN*),

465 chromatin modeling (*CHD7*, *KMT2D*, *NSD1*), transcriptional regulations (*GATA6*), and cell

466 structural support (*ACTB, RPL5*) [42, 43].



492

493 *POGZ*, *KDM5B*, and *NAA15* are all highly expressed in developmental heart at mice embryonic 494 day E14.5 [4]. *POGZ* and *NAA15* are intolerant for both LoF and missense mutations, given that 495 they have a pLI score > 0.9 and a missense z-score > 3. *KDM5B* is intolerant for missense 496 mutations with a missense z-score of 1.78. Considering their intolerance of protein-altering 497 variants, the identification of damaging *de novo* mutations in them is highly unlikely. Therefore, 498 our analyses suggest that *POGZ*, *KDM5B* and *NAA15* may be considered as new candidate 499 CHD genes.

500

501 Furthermore, among the 17 genes with at least one *de novo* mutation in CHD and autism

502 cohorts, 5 genes (*KMT2D*, *NSD1*, *POGZ*, *SMAD2*, *KDM5B*) play a role in chromatin modeling.

503 Such high proportion is consistent with previous studies that chromatin modeling-related

504 transcriptional regulations are essential for both cardiac and neuro-development, and genes

505 with critical regulatory roles in the process may be pleotropic [9].

506

507 Further, we compared the performance of M-DATA with mTADA [23] using the same real data 508 of CHD and autism. We fitted both methods with damaging mutations (LoF and Dmis mutations). 509 mTADA identified all 18 genes identified by our no annotation model, and missed 3 genes 510 (*CDK13*, *SAMD11,* and *RPL5*) identified by our annotation model for CHD (Table 2). We 511 visualized the results with Venn diagrams (Fig 6 and Fig J in the S1 Text). We also compared 512 our results with the results of CHD-ASD pair reported by mTADA using CHD data [55] autism 513 data [11], and mutability data downloaded from the github webpage of mTADA (Table E in the 514 S1 Text).



515 **Table 3. Comparison of M-DATA multi-trait models with mTADA**

medRxiv preprint doi: [https://doi.org/10.1101/2021.05.22.21257421;](https://doi.org/10.1101/2021.05.22.21257421) this version posted September 7, 2021. The copyright holder for this preprint<br>(which was not certified by peer review) is the author/funder, who has grante





517 **Fig 7. Venn diagram of genes identified by M-DATA and mTADA for CHD.** M-DATA multi-trait model with 518 annotations identified 3 additional genes *(CDK13, SAMD11* and *RPL5).* 

519

# 520 **Discussion**

521 In this paper, we have introduced M-DATA, a method to jointly analyze *de novo* mutations from 522 multiple traits by integrating shared genetic information across traits. The implemented model is 523 available at https://github.com/JustinaXie/MDATA. This approach can increase the effective 524 sample size for all traits, especially for those with small sample size. M-DATA also provides a 525 flexible framework to incorporate external functional annotations, either variant-level or gene-526 level, which can further improve the statistical power. Through simulation study, we 527 demonstrated that our multi-trait model with annotations could not only gain accurate estimates 528 on the proportion of shared risk genes between two traits and the proportion of risk genes for a 529 single trait under various settings, but also gained statistical power compared to the single-trait 530 models. In addition, M-DATA adopts the Expectation-Maximization (EM) algorithm in estimation, It is made scalistic truder a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .<br>
M-DATA No<br>
(0.0%)<br>
(1.10%)<br>
(0.0%)<br>
(1.10%)<br>
(0.0%)<br>
(1.10%)<br>
(0.0%)<br>
(1.10%)<br>

531 which does not require prior parameter specification or pre-estimation. In our simulation study, 532 we found that the algorithm converges faster than methods that use MCMC for estimation 533 (Table D in the S1 Text).

534

535 Despite the success, there are some limitations in the current M-DATA model. In our real data 536 analysis, we used two different data sources for CHD and autism. Samples with both diseases 537 in our multi-trait analysis may bring bias because of the violation of independence assumption in 538 our multi-trait models. The autism DNM data in our analysis are from different studies, and 539 different filtering criteria across studies may also bring bias and dilute our signals. In addition, 540 we only considered two traits simultaneously. Though it is straightforward to extend our model to more than two traits, the number of groups (i.e., the dimension of latent variables  $\boldsymbol{Z}_i$ <br>increases exponentially with the number of traits (2<sup>N</sup> for N traits) [23]. This might bring 541 to more than two traits, the number of groups (i.e., the dimension of latent variables  $Z_i$ ) 542 increases exponentially with the number of traits (2<sup>x</sup> for N traits) [23]. This might bring difficulty<br>543 in estimation and have more computational cost. Model performance with more than two traits 543 in estimation and have more computational cost. Model performance with more than two traits 544 need further exploration. Currently, we did not consider the influence of admixed population in 545 M-DATA. In a recent study, Kessler et al. studied DNM across 1,465 diverse genomes and 546 discovered mutation rates may be affected by the environment more significantly than 547 previously known [56]. Confounding from the environment on mutation rates could be further 548 explored through cross-ancestry rare variant studies.

549

550 In conclusion, M-DATA is a novel and powerful approach to performing gene-based association 551 analysis for DNMs across multiple traits. Not only does M-DATA have better statistical power 552 than single-trait methods, it also provides reasonable estimation of shared proportion of risk 553 genes between two traits, which gives novel insights in the understanding of disease 554 mechanism. We have successfully applied M-DATA to study CHD, which identified significant 555 23 genes for our multi-trait model with annotations. Moreover, our method provides a general 556 framework in extending single-trait method to multi-trait method which can also incorporate

<u>29 and 29 and 20</u>

- 557 information from functional annotations. Recently, there are several advancements in the
- 558 association analysis for rare variants, such as jointly analyzing DNMs and transmitted variants
- 559 [41], analyzing DNMs from whole-genome sequencing (WGS) data [25], and incorporating
- 560 pathway information [57]. Extension of these methods to multi-trait analysis is a potential future
- 561 direction.
- 562

### 563 *Ethics Statement*

- 564 This study is approved by Yale Human Research Protection Program Institutional Review
- 565 Boards (IRB protocol ID 2000028735).
- 566

# 567 **Supporting Information**

- 568 **S1 Table. Simulation of Estimation and Power Evaulation.**
- 569 **S2 Table. Simulation of Comparison with mTADA.**
- 570 **S3 Table. Results of Real Data Application.**
- 571 **S1 Text. Supplementary Notes on Methods and Results.**

572

### 573 **Acknowledgements**

- 574 Supported in part by NIH grant R03HD100883-01A1. We thank Dr. Sheng Chih (Peter) Jin,
- 575 Geyu Zhou and Hanmin Guo for helpful discussions.

576

577 **References** 

578 1. Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, et al. De novo mutations in<br>histone-modifying genes in congenital heart disease. Nature. 2013;498(7453):220-3. Epub<br>2013/05/12. doi: 10.1038/nature12141. PubMed PM 1. 579 580

2. Postma AV, Bezzina CR, Christoffels VM. Genetics of congenital heart disease: the 2013/05/12. doi: 10.1038/nature12141. PubMed PMID: 23665959. 581 contribution of the noncoding regulatory genome. Journal of Human Genetics. 2016;61(1<br>doi: 10.1038/jhg.2015.98. 582 583

doi: 10.1038/jhg.2015.98.<br>3. Wienke A, Herskind AM, Christensen K, Skytthe A, Yashin AI. The heritability of CHD mortality in danish twins after controlling for smoking and BMI. Twin Res Hum Genet. 584 mortality in danish twins after controlling for smoking and BMI. Twin Res Hum Genet.<br>2005;8(1):53-9. Epub 2005/04/20. doi: 10.1375/1832427053435328. PubMed PMID: 15836 585

mortally in danish twins after controlling for successive controlling for success.<br>2005;8(1):53-9. Epub 2005/04/20. doi: 10.1375/1832427053435328. PubMed PMID: 1<br>4. Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma 586 2005;8(1):53-9. Epub 2005/04/20. doi: 10.1375/1832427053435328. PubMed PMID: 15836811. 587 4. Jim Scy, Homsy J, Zamery, Zang, Morron Sy, 200 milion, Sound Schen Schen Schen Schen Inherited<br>and de novo variants in 2,871 congenital heart disease probands. Nat Genet. 2017;49(11):1593-<br>601. Epub 2017/10/11. doi: 10. 588 601. Epub 2017/10/11. doi: 10.1038/ng.3970. PubMed PMID: 28991257; PubMed Central PMCID: PMCPMC5675000. 589 590

5. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, et al. De novo 5. Sanders SJ, Murtha<br>mutations revealed by who 591 mutations revealed by whole-exome sequencing are strongly associated with autism. Nature.<br>2012;485(7397):237-41. Epub 2012/04/13. doi: 10.1038/nature10945. PubMed PMID: 592 2012;485(7397):237-41. Epub 2012/04/13. doi: 10.1038/nature10945. PubMed PMID:<br>22495306; PubMed Central PMCID: PMCPMC3667984. 593 594

6. He X, Sanders SJ, Liu L, De Rubeis S, Lim ET, Sutcliffe JS, et al. Integrated model of de novo and inherited genetic variants yields greater power to identify risk genes. PLoS Genet. 595 novo and inherited genetic variants yields greater power to identify risk genes. PLoS Genet.<br>2013;9(8):e1003671. Epub 2013/08/24. doi: 10.1371/journal.pgen.1003671. PubMed PMID: 596 2013;9(8):e1003671. Epub 2013/08/24. doi: 10.1371/journal.pgen.1003671. PubMed PMID:<br>23966865; PubMed Central PMCID: PMCPMC3744441. 597 23966865; PubMed Central PMCID: PMCPMC3744441.<br>7. Coe BP, Stessman HAF, Sulovari A, Geisheker MR, Bakken TE, Lake AM, et al. 598

Neurodevelopmental disease genes implicated by de novo mutation and copy number variation 599 7. Coercessing Coe Bakken Harmon, Sulovan Harmon, Summari A, Sulovan, Sulovan<br>19. Neurodevelopmental disease genes implicated by de novo mutation and copy numb<br>19. morbidity. Nature Genetics. 2019;51(1):106-16. doi: 10.103 600 morbidity. Nature Genetics. 2019;51(1):106-16. doi: 10.1038/s41588-018-0288-4.<br>8. Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, Franke L, et al. Meta-601

8. Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, Franke L, et al. Meta-<br>analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies 602 8. Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, Franke L, et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies 603 604 10.1371/journal.pgen.1002004. PubMed PMID: 21383967; PubMed Central PMCID:<br>PMCPMC3044685. 605 606

9. Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ, et al. De novo mutations 9. Homsy J, Za<br>in congenital heart 607 in congenital heart disease with neurodevelopmental and other congenital anomalies. Science.<br>2015;350(6265):1262-6. Epub 2016/01/20. doi: 10.1126/science.aac9396. PubMed PMID: 608 2015;350(6265):1262-6. Epub 2016/01/20. doi: 10.1126/science.aac9396. PubMed PMID:<br>26785492; PubMed Central PMCID: PMCPMC4890146. 609 610

20. Willsey AJ, Morris MT, Wang S, Willsey HR, Sun N, Teerikorpi N, et al. The Psychiatric Cell 26785492; PubMed Central PMCID: PMCPMC4890146. 611 612

11. Williams, M. Morris Mil, Mang S, Millsey Mil, Santry, Morris Pril, Southworce, Millsey The Psychiatric Cel<br>Map Initiative: A Convergent Systems Biological Approach to Illuminating Key Molecular<br>Pathways in Neuropsychia Pathways in Neuropsychiatric Disorders. Cell. 2018;174(3):505-20. Epub 2018/07/28. doi: 613

10.1016/j.cell.2018.06.016. PubMed PMID: 30053424; PubMed Central PMCID:<br>PMCPMC6247911. 614

615

11. Nguyen HT, Bryois J, Kim A, Dobbyn A, Huckins LM, Munoz-Manchado AB, et al. 616

Integrated Bayesian analysis of rare exonic variants to identify risk genes for schizophrenia and اس کرد.<br>Integrated Bayesian analysis of rare exonic variants to identify risk genes for schizophre<br>Ineurodevelopmental disorders. Genome Med. 2017;9(1):114. Epub 2017/12/22. doi: 617

Integrated Bayesian analysis of rare extends formule of mentify risk genes for sendepth sind and<br>neurodevelopmental disorders. Genome Med. 2017;9(1):114. Epub 2017/12/22. doi:<br>10.1186/s13073-017-0497-y. PubMed PMID: 292628 618

10.1186/s13073-017-0497-y. PubMed PMID: 29262854; PubMed Central PMCID:<br>PMCPMC5738153. 619 10.1186/s13073-017-0497-y. PubMed PMID: 29262854; PubMed Central PMCID:

621 12. by four neuropsychiatric disorders discovered from NPdenovo database. Mol Psychiatry.<br>2016;21(2):290-7. Epub 2015/04/08. doi: 10.1038/mp.2015.40. PubMed PMID: 25849321; 622 )<br>2016;21(2):290-7. Epub 2015/04/08. doi: 10.1038/mp.2015.40. PubMed PMID: 2584932:<br>PubMed Central PMCID: PMCPMC4837654. 623 624 PubMed Central PMCID: PMCPMC4837654.<br>13. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. 13. Giambartolomei C, Vukcevic D, Schac<br>Bayesian test for colocalisation between pai 625 13. Giamman comes by the control by control by Common, Amgermanne, Common, Schar<br>Bayesian test for colocalisation between pairs of genetic association studies using summar<br>statistics. PLoS Genet. 2014;10(5):e1004383. Epub 626 est, entit for colocalisation between pairs of generic association between pairs of genetic associations, and<br>statistics. PLoS Genet. 2014;10(5):e1004383. Epub 2014/05/17. doi:<br>10.1371/journal.pgen.1004383. PubMed PMID: 24 627 10.1371/journal.pgen.1004383. PubMed PMID: 24830394; PubMed<br>PMCPMC4022491. 628 629 PMCPMC4022491.<br>14. Solovieff N, Cotsapas C, Lee PH, Purcell SM, Smoller JW. Pleiotropy in complex traits: - - - - - - - - - - - - - - -<br>14. Solovieff N,<br>challenges and stra 630 - Allenges and strategies. Nat Rev Genet. 2013;14(7):483-95. Epub 2013/06/12. doi:<br>10.1038/nrg3461. PubMed PMID: 23752797; PubMed Central PMCID: PMCPMC4104202. 631 632 10.1038/nrg3461. PubMed PMID: 23752797; PubMed Central PMCID: PMCPMC4104202.<br>15. Chung D, Yang C, Li C, Gelernter J, Zhao H. GPA: a statistical approach to prioritizing 633 سبي ) who SwaS results by integrating pleiotropy and annotation. PLoS Genet. 2014;10(11):e1004787<br>Epub 2014/11/14. doi: 10.1371/journal.pgen.1004787. PubMed PMID: 25393678; PubMed 634 GWAS results by integrating pleiotropy and annotation. PLoS Genet. 2014;10(11): e1004787. Epub 2014/11/14. doi: 10.1371/journal.pgen.1004787. PubMed PMID: 25393678; PubMed<br>Central PMCID: PMCPMC4230845. 635 636 Central PMCID: PMCPMC4230845.<br>16. Plutre T, Wen X, Pritchard J, Stephens M. A statistical framework for joint eQTL analysis 637 in multiple tissues. PLoS Genet. 2013;9(5):e1003486. Epub 2013/05/15. doi:<br>10.1371/journal.pgen.1003486. PubMed PMID: 23671422; PubMed Central PMCID: 638 in multiple tissues. PLoS Genet. 2013;9(5):e1003486. Epub 2013/05/15. doi: 10.1371/journal.pgen.1003486. PubMed PMID: 23671422; PubMed Central<br>PMCPMC3649995. 639 640 PMCPMC3649995.<br>17. Sul JH, Han B, Ye C, Choi T, Eskin E. Effectively identifying eQTLs from multiple tissues by 641 17. Sul JH, Han B, Ye C, Choi T, Eskin E. Effectively identifying eQTLs from multiple tissues by 642 combining mixed model and meta-analytic approaches. PLoS Genet. 2013;9(6):e1003491. Epub combining military model and meta-analytic approaches. Plot a local local computer of the lappinity<br>2013/06/21. doi: 10.1371/journal.pgen.1003491. PubMed PMID: 23785294; PubMed Central<br>PMCID: PMCPMC3681686. 643 644 PMCID: PMCPMC3681686.<br>18. Duong D, Gai L, Snir S, Kang EY, Han B, Sul JH, et al. Applying meta-analysis to genotype-645 646 tissue expression data from multiple tissues to identify eQTLs and increase the number of eGenes. Bioinformatics. 2017;33(14):i67-i74. Epub 2017/09/09. doi:<br>10.1093/bioinformatics/btx227. PubMed PMID: 28881962; PubMed Central PMCID: 647 eGenes. Bioinformatics. 2017;33(14):i67-i74. Epub 2017/09/09. doi: edences. Biometer. Bion. 2017;<br>10.1093/bioinformatics/btx227. PubMed PMID: 28881962; PubMed<br>PMCPMC5870567. 648 649 PMCPMC5870567.<br>19. Li G, Jima D, Wright FA, Nobel AB. HT-eQTL: integrative expression quantitative trait loci 650 analysis in a large number of human tissues. BMC Bioinformatics. 2018;19(1):95. Epub<br>2018/03/11. doi: 10.1186/s12859-018-2088-3. PubMed PMID: 29523079; PubMed Central 651 analysis in a large number of human tissues. BMC Bioinformatics.  $2018;19(1):95$ . Epub analysis in a large number of human tissues. Bioing Economical LCD/LCD, C, C, C is a pub.<br>2018/03/11. doi: 10.1186/s12859-018-2088-3. PubMed PMID: 29523079; PubMed Cen<br>PMCID: PMCPMC5845327. 652 653 PMCID: PMCPMC5845327.<br>20. Li C, Yang C, Gelernter J, Zhao H. Improving genetic risk prediction by leveraging 20. Li C, Yang C, Gelern<mark>t</mark><br>pleiotropy. Hum Genet. 201 654 20. Li C, Yang C, Gerernter C, 2014; 1330.<br>pleiotropy. Hum Genet. 2014; 133(5):639-50. Epub 2013/12/18. doi: 10.1007/s00439-01<br>5. PubMed PMID: 24337655; PubMed Central PMCID: PMCPMC3988249. 655 656 5. PubMed PMID: 24337655; PubMed Central PMCID: PMCPMC3988249.<br>21. Maier R. Moser G. Chen GB. Ripke S. Coryell W. Potash JB. et al. Joint analysis of 21. Maier R, Moser G, Chen GB, Ripke S, Coryell W, Potash JB, et al. Jo<br>psychiatric disorders increases accuracy of risk prediction for schizophren 657 22. March R, Moser G, Chen GB, Riphe S, Coryell W, Potash C, Commonw, Corp.<br>21. psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disc<br>2015/02/03. and major depressive disorder. Am J Hu 658 psychiatric discreases accuracy of risk prediction forms prediction, appearance of<br>and major depressive disorder. Am J Hum Genet. 2015;96(2):283-94. Epub 2015/02/03. doi:<br>10.1016/j.ajhg.2014.12.006. PubMed PMID: 25640677; 659 10.1016/j.ajhg.2014.12.006. PubMed PMID: 25640677; PubMed Central PMCID:<br>PMCPMC4320268. 660 661 PMCPMC4320268.<br>22. Hu Y, Lu Q, Liu W, Zhang Y, Li M, Zhao H. Joint modeling of genetically correlated PHACH PHEFET<br>22. Hu Y, Lu Q, I<br>diseases and function 662 diseases and functional annotations increases accuracy of polygenic risk prediction. PLoS 663 diseases and functional annotations increases accuracy of polygenic risk prediction. PLoS Genet.

664 2017;13(6):e1006836. Epub 2017/06/10. doi: 10.1371/journal.pgen.1006836. PubMed PMID:<br>28598966; PubMed Central PMCID: PMCPMC5482506.<br>23. Nguyen T-H, Dobbyn A, Brown RC, Riley BP, Buxbaum JD, Pinto D, et al. mTADA is 665

23. Nguyen T-H, Dobbyn A, Brown RC, Riley BP, Buxl<br>framework for identifying risk genes from de novo muta 666  $\frac{2}{3}$ . The work for identifying risk genes from de novo mutations in multiple traits. Nature<br>Communications. 2020;11(1):2929. doi: 10.1038/s41467-020-16487-z. 667 668

Communications. 2020;11(1):2929. doi: 10.1038/s41467-020-16487-z.<br>24. Lu Q, Yao X, Hu Y, Zhao H. GenoWAP: GWAS signal prioritization through integrated Communications. 2020;11(1):2929. doi: 10.1038/s41467-020-16487-z. 669 23. Lu Carlo, Yao Y, Yang, Maria ya Tana Maria ya Maria ya Nagaria prioritization the signal prioritization<br>analysis of genomic functional annotation. Bioinformatics. 2016;32(4):542-8. Epub 2015/10<br>doi: 10.1093/bioinformat 670 doi: 10.1093/bioinformatics/btv610. PubMed PMID: 26504140; PubMed Central PMCID:<br>PMCPMC5963360. 671 672

25. Liu Y, Liang Y, Cicek AE, Li Z, Li J, Muhle RA, et al. A Statistical Framework for Mapping PHACES SESSEN<br>25. Liu Y, Liang<br>Risk Genes from De 673 25. Liu Y, Liung Y, Lium II, Liu, Muhle Ra, Lium Chancella Framework for Mapping<br>Risk Genes from De Novo Mutations in Whole-Genome-Sequencing Studies. Am J Hum Genet<br>2018;102(6):1031-47. Epub 2018/05/15. doi: 10.1016/j.ajh 674 2018;102(6):1031-47. Epub 2018/05/15. doi: 10.1016/j.ajhg.2018.03.023. PubMed PMID:<br>29754769; PubMed Central PMCID: PMCPMC5992125. 675 676

26. Butkiewicz M, Blue EE, Leung YY, Jian X, Marcora E, Renton AE, et al. Functional 26. Butkiewicz M, Blue EE, Leung YY, Jian X, Marcora<br>annotation of genomic variants in studies of late-onset . 677 annotation of genomic variants in studies of late-onset Alzheimer's disease. Bioinforma<br>2018;34(16):2724-31. doi: 10.1093/bioinformatics/bty177. 678 679

2018;34(16):2724-31. doi: 10.1093/bioinformatics/bty177.<br>27. Samocha KE, Robinson EB, Sanders SJ, Stevens C, Sabo A, McGrath LM, et al. A 680

framework for the interpretation of de novo mutation in human disease. Nat Genet. framework for the interpretation of de novo mutation in human disease. Nat Genet.<br>2014;46(9):944-50. Epub 2014/08/05. doi: 10.1038/ng.3050. PubMed PMID: 2508666 681

2014;46(9):944-50. Epub 2014/08/05. doi: 10.1038/ng.3050. PubMed PMID: 250866<br>PubMed Central PMCID: PMCPMC4222185. 682 683

PubMed Central PMCID: PMCPMC4222185.<br>28. Mo Li XZ, Chentian Jin, Sheng Chih Jin, Weilai Dong, Martina Brueckner, Richard Lifton, 28. Mo Li XZ, Chentian Jin, Sheng Chih Jir<br>Qiongshi Lu, Hongyu Zhao. Integrative mode 684 28. Monten 2002, Chemanning Chin Jin, Sheng Chin Jin, Sheng Chip, Martina Brueckner, Martina Brueck,<br>Qiongshi Lu, Hongyu Zhao. Integrative modeling of transmitted and *de novo* variants identifies<br>novel risk genes for cong 685 Qiongshi Lu, Hongyu Zhao. Integrative modeling of transmitted and *de novo* variants identifies<br>686 novel risk genes for congenital heart disease. Quant Biol.0-\${article.jieShuYe}. doi: 10.15302/j-<br>687 ob-021-0248. 686 687

29. Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and qareaareaa.<br>29. Yang H<br>wANNOVAR. 1 688 20. Yang H, Wang A. Genomic variant annotation and processes transmitted and ana<br>WANNOVAR. Nat Protoc. 2015;10(10):1556-66. Epub 2015/09/18. doi: 10.1038/nprot.2015.<br>PubMed PMID: 26379229; PubMed Central PMCID: PMCPMC47187 689 690

PubMed PMID: 26379229; PubMed Central PMCID: PMCPMC4718734.<br>30. Kim S, Jhong J-H, Lee J, Koo J-Y. Meta-analytic support vector machine for integrating PubMed PMP PubMed PubMed Central PMP PubMed Central Politics<br>30. Kim S, Jhong J-H, Lee J, Koo J-Y. Meta-analytic support vector ma<br>multiple omics data. BioData Mining. 2017;10(1):2. doi: 10.1186/s1304 691 33. Kim S, Heng Pryse Cynter Protein analytic support vector mathine for integrating<br>multiple omics data. BioData Mining. 2017;10(1):2. doi: 10.1186/s13040-017-0126-8.<br>31. Karczewski KJ, Francioli LC, Tiao G, Cummings 692

31. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The<br>mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 693 31. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The 694 695

mutational constraint spectrum quantified from variation in 141,457 humans. Nature.<br>2020;581(7809):434-43. doi: 10.1038/s41586-020-2308-7.<br>32. Moon TK. The expectation-maximization algorithm. IEEE Signal Processing M  $32.\quad\quad$  Moon TK. The expectation-maximization algorithm.<br>1996;13(6):47-60. doi: 10.1109/79.543975. 696 32. Moon TK. The expectation-maximization algorithm. IEEE Signal Processing Magazine<br>1996;13(6):47-60. doi: 10.1109/79.543975.<br>33. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missen 697

698

mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013; Chapter 7: Unit 7.20. Epub mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;Chapter 7:Unit7.20. Epub<br>2013/01/15. doi: 10.1002/0471142905.hg0720s76. PubMed PMID: 23315928; PubMed Cen 699

2013/01/15. doi: 10.1002/0471142905.hg0720s76. PubMed PMID: 23315928; PubMe<br>PMCID: PMCPMC4480630. 700 701

PMCID: PMCPMC4480630.<br>34. Samocha KE, Kosmicki JA, Karczewski KJ, O'Donnell-Luria AH, Pierce-Hoffman E, - AMAN AMAN AMAN AMAN<br>34. Samocha KE, Kosmid<br>MacArthur DG, et al. Regior 702

MacArthur DG, et al. Regional missense constraint improves variant deleteriousness pre<br>BioRxiv. 2017:148353. 703 BioRxiv. 2017:148353.<br>35. MacArthur M. Witten DM, Jain P. O'Roak BJ. Cooper GM, Shendure J. A general framework 704

BioRxiv. 2017:148353. 35. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework 705 706 for estimating the relative pathogenicity of human genetic variants. Natural 2014; $\frac{1}{2}$ ;  $\frac{1}{2}$ ;  $\frac{1}{2}$ ;  $\frac{1}{2}$ 

707 5. Epub 2014/02/04. doi: 10.1038/ng.2892. PubMed PMID: 24487276; PubMed Central PMCID:<br>PMCPMC3992975.<br>36. loannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: 708

709

An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum<br>Genet. 2016;99(4):877-85. Epub 2016/09/27. doi: 10.1016/j.ajhg.2016.08.016. PubMed PMID: 710

Genet. 2016;99(4):877-85. Epub 2016/09/27. doi: 10.1016/j.ajhg.2016.08.016. PubMed PMI<br>27666373; PubMed Central PMCID: PMCPMC5065685. 711

712

27666373; PubMed Central PMCID: PMCPMC5065685.<br>37. Jian X, Boerwinkle E, Liu X. In silico prediction of splice-altering single nucleotide variants 2766667777888687788868778868687.<br>27. Jian X, Boerwinkle E, Liu X. In silico prediction of<br>in the human genome. Nucleic Acids Research. 2014;42 713 in the human genome. Nucleic Acids Research. 2014;42(22):13534-44. doi:<br>10.1093/nar/gku1206. 714

715

10.1093/nar/gku1206.<br>38. Xiong HY, Alipanahi B, Lee LJ, Bretschneider H, Merico D, Yuen RKC, et al. The human -------, ...., *graaf*<br>38. Xiong HY, Alipar<br>splicing code reveals ne 716 38. Young Hy, Alipanahi B, Lee Ly, Bretschneider H, Merico B, Yuen Aney, 2014. The humani<br>splicing code reveals new insights into the genetic determinants of disease. Science.<br>2015;347(6218):1254806. doi: 10.1126/science.1 717

718

2015;347(6218):1254806. doi: 10.1126/science.1254806.<br>39. Jiang W, Yu W. Controlling the joint local false discovery rate is more powerful than 2023;347(2022):2254806. 2016. 2022):2254806.<br>20. Jiang W, Yu W. Controlling the joint local false disc<br>meta-analysis methods in joint analysis of summary statis! 719 meta-analysis methods in joint analysis of summary statistics from multiple genome-wide<br>association studies. Bioinformatics. 2016;33(4):500-7. doi: 10.1093/bioinformatics/btw690. 720

association studies. Bioinformatics. 2016;33(4):500-7. doi: 10.1093/bioinformatics/btw690.<br>40. Turner TN, Yi Q, Krumm N, Huddleston J, Hoekzema K, HA FS, et al. denovo-db: a 721

association studies. Biomeration studies. 2017;33, 2016;33(4):2016;33(4):2016;33(4):2016;33(4):2016;<br>2016;33(4):500-7. doi: 10.1093/bioinformatics. 2017;45(101):10904-11. doi: 10.1090. doi: 10.1099. doi: 10.109<br>2017;45(D1) 722 compendium of human de novo variants. Nucleic Acids Res. 2017;45(D1):D804-d11. Epul<br>2016/12/03. doi: 10.1093/nar/gkw865. PubMed PMID: 27907889; PubMed Central PMC 723 2016/12/03. doi: 10.1093/nar/gkw865. PubMed PMID: 27907889; PubMed Central PMCID:<br>PMCPMC5210614. 724 725

41. Li M. Gene-based Association Analysis for Genome-wide Association and Whole-exome Sequencing Studies: Yale University; 2020. 726 727

42. Zaidi S, Brueckner M. Genetics and Genomics of Congenital Heart Disease. Circ Res. Sequencing Studies: Yale University; 2020. 728 . 2017;120(6):923-40. Epub 2017/03/18. doi: 10.1161/circresaha.116.309140. PubMed PMID<br>28302740; PubMed Central PMCID: PMCPMC5557504. 729 730

28302740; PubMed Central PMCID: PMCPMC5557504.<br>43. Pierpont ME, Brueckner M, Chung WK, Garg V, Lacro RV, McGuire AL, et al. Genetic 2830292027774. PubMed Central Power Central PowerPole<br>43. Pierpont ME, Brueckner M, Chung WK, Garg V, L<br>Basis for Congenital Heart Disease: Revisited: A Scientifi 731 44. Pierpont ME, Englands M, Chung WY, Chung V, Chunc M, McCulic VI, Chunc Prosince<br>Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American He<br>Association. Circulation. 2018;138(21):e653-e71 732 Association. Circulation. 2018;138(21):e653-e711. Epub 2018/12/21. doi:<br>10.1161/cir.00000000000000606. PubMed PMID: 30571578; PubMed Central PMCID: 733

Association. Circulation. 2019;138(21):0012-012-012-012-012-012-012.<br>10.1161/cir.0000000000000606. PubMed PMID: 30571578; PubMed Cent<br>PMCPMC6555769. 734 735

PMCPMC6555769.<br>44. McKean DM, Homsy J, Wakimoto H, Patel N, Gorham J, DePalma SR, et al. Loss of RNA 44. McKean D<mark>N</mark><br>expression and alle 736 expression and allele-specific expression associated with congenital heart disease. Nat Commi<br>2016;7:12824. Epub 2016/09/28. doi: 10.1038/ncomms12824. PubMed PMID: 27670201; 737

2016;7:12824. Epub 2016/09/28. doi: 10.1038/ncomms12824. PubMed PMID: 27670201;<br>PubMed Central PMCID: PMCPMC5052634. 738

739

45. Verma SK, Deshmukh V, Nutter CA, Jaworski E, Jin W, Wadhwa L, et al. Rbfox2 function 45. Verma SK, Deshmukh V, Nutter CA, J.<br>in RNA metabolism is impaired in hypoplasti 740 45. Verma Sky, Deshman V, Nutter CA, Jaworski B, Jin W, Walkshing, Deal. Rhotter Chronol.<br>1988. – In RNA metabolism is impaired in hypoplastic left heart syndrome patient hearts. Sci Rep.<br>2016;6:30896. Epub 2016/08/04. doi 741

2016;6:30896. Epub 2016/08/04. doi: 10.1038/srep30896. PubMed PMID: 27485310; PubMed<br>Central PMCID: PMCPMC4971515. 742 743

46. Granadillo JL, Chung WK, Hecht L, Corsten-Janssen N, Wegner D, Nij Bijvank SWA, et al. Variable cardiovascular phenotypes associated with SMAD2 pathogenic variants. Hum Mutat. 744 46. Grandom D. J. Chung W., Chung Western L, Chung Will, Chung W., Corsten, J. Corsten, J. Corsten, J. Corsten<br>1991 - Variable cardiovascular phenotypes associated with SMAD2 pathogenic variants. Hum Mutat.<br>2018;39(12):187 745

.<br>2018;39(12):1875-84. Epub 2018/08/30. doi: 10.1002/humu.23627. PubMed PMID: 30157302<br>47. Sifrim A, Hitz MP, Wilsdon A, Breckpot J, Turki SH, Thienpont B, et al. Distinct genetic 746

47. Sifrim A, Hitz MP, Wilsdon A, Breckpot J, Turki SH, Thienpont B, et al. Distinct genetic<br>architectures for syndromic and nonsyndromic congenital heart defects identified by exome 747

47. Similary, Millim, Johnson A, Breckpot, Ammery, Michiponte, Component General<br>architectures for syndromic and nonsyndromic congenital heart defects identified by exome<br>sequencing. Nat Genet. 2016;48(9):1060-5. Epub 2016 748

sequencing. Nat Genet. 2016;48(9):1060-5. Epub 2016/08/02. doi: 10.1038/ng.3627. PubMe<br>PMID: 27479907; PubMed Central PMCID: PMCPMC5988037. 749

PMID: 27479907; PubMed Central PMCID: PMCPMC5988037. 750 PMID: 27479907; PubMed Central PMCID: PMCPMC5988037.

751 48. Stessman HAF, Willemsen MH, Fenckova M, Penn O, Hoischen A, Xiong B, et al.<br>Disruption of POGZ Is Associated with Intellectual Disability and Autism Spectrum Disorders. Am 48. 752 753 J Hum Genet. 2016;98(3):541-52. Epub 2016/03/05. doi: 10.1016/j.ajhg.2016.02.004. PubMed<br>PMID: 26942287; PubMed Central PMCID: PMCPMC4890241. 754 755 49. Matsumura K, Seiriki K, Okada S, Nagase M, Ayabe S, Yamada I, et al. Pathogenic POGZ 49. Matsumura K, Seiman, Seiman, Angels K, Ayabe S, Amada I, Seiman, Seiman, Seiman<br>1997. Matsum Saussen in paired cortical development and reversible autism-like phenotypes. Nat<br>1997-2. PubMed PMII 756 mutation causes impaired cortical development and reversible autism-like phenotypes. Nat mutation causes impaired cortical development and reversion cortical presents, presents<br>Commun. 2020;11(1):859. Epub 2020/02/28. doi: 10.1038/s41467-020-14697-z. PubMed PN<br>32103003; PubMed Central PMCID: PMCPMC7044294 decl 757 32103003; PubMed Central PMCID: PMCPMC7044294 declare no competing interests.<br>50. White J, Beck CR, Harel T, Posey JE, Jhangiani SN, Tang S, et al. POGZ truncating alleles 758 3221111, PubMed Central Protect Medicines Process Protect Central Protect Prosess.<br>30. White J, Beck CR, Harel T, Posey JE, Jhangiani SN, Tang S, et al. POGZ truncating<br>cause syndromic intellectual disability. Geno 759 53. White J, Beck CR, Harel T, Posey Ca, Hangamerry Pang S, Cran Posetan Harmanng and Cr<br>cause syndromic intellectual disability. Genome Med. 2016;8(1):3. Epub 2016/01/08. doi:<br>10.1186/s13073-015-0253-0. PubMed PMID: 26739 760 cause syndromic intellectual disability. Genome Medical displayers by an Essay, 2016.<br>10.1186/s13073-015-0253-0. PubMed PMID: 26739615; PubMed Central PMCID:<br>PMCPMC4702300. 761 762 PMCPMC4702300.<br>51. Kidder BL, Hu G, Zhao K. KDM5B focuses H3K4 methylation near promoters and 763 enhancers during embryonic stem cell self-renewal and differentiation. Genome Biol.<br>2014;15(2):R32. Epub 2014/02/06. doi: 10.1186/gb-2014-15-2-r32. PubMed PMID: 244! 764 enhancers during embryonic stem cell self-renewal and differentiation. Genome Biol. 2014;15(2):R32. Epub 2014/02/06. doi: 10.1186/gb-2014-15-2-r32. PubMed PMID: 24<br>PubMed Central PMCID: PMCPMC4053761. 765 766 PubMed Central PMCID: PMCPMC4053761.<br>2015: Experis 2015. Kundeanu II, Kidder BL. Contribution of H3K4 demethylase KDM5B to 52. Kurup JT, Campeanu IJ, Kidder BL. Co<br>nucleosome organization in embryonic stem 767 nucleosome organization in embryonic stem cells revealed by micrococcal nuclease seq<br>Epigenetics Chromatin. 2019;12(1):20. Epub 2019/04/04. doi: 10.1186/s13072-019-026 768 769 Epigenetics Chromatin. 2019;12(1):20. Epub 2019/04/04. doi: 10.1186/s13072-019-0266-9.<br>PubMed PMID: 30940185; PubMed Central PMCID: PMCPMC6444878. 770 53. Albert M, Schmitz SU, Kooistra SM, Malatesta M, Morales Torre:<br>histone demethylase Jarid1b ensures faithful mouse development by pı 771 53. Albert M, Schmitz SU, Kooistra SM, Malatesta M, Morales Torres C, Rekling JC, et al. The 53. Albert M, Schmitz SU, M. Schmitz M, Manatesta M, Merches Torres C, Manniges, Sean Michael<br>histone demethylase Jarid 1b ensures faithful mouse development by protecting developmental<br>genes from aberrant H3K4me3. PLoS Ge 772 773 genes from aberrant H3K4me3. PLoS Genet. 2013;9(4):e1003461. Epub 2013/05/03. doi:<br>10.1371/journal.pgen.1003461. PubMed PMID: 23637629; PubMed Central PMCID: o<br>10.1371/journal.pgen.1003461. PubMed PMID: 23637629; PubMed Central PMCID:<br>PMCPMC3630093 other authors have declared that no competing financial interests exist 774 10.1371/journal.pgen.1003461. PubMed PMID: 23637629; PubMed Central PMCID: 775 776 54. Cheng H, Dharmadhikari AV, Varland S, Ma N, Domingo D, Kleyner R, et al. Truncating<br>Variants in NAA15 Are Associated with Variable Levels of Intellectual Disability, Autism 777 Variants in Are Chromotographs in Namale Levels of Intellectual Lemann, Authors<br>Spectrum Disorder, and Congenital Anomalies. Am J Hum Genet. 2018;102(5):985-94. I<br>2018/04/17. doi: 10.1016/j.ajhg.2018.03.004. PubMed PMID: 2 778 Spectrum Disorder, and Congenital Anomalies. Am J Hum Genet. 2018;102(5):985-94. Epub spectrum Discorder, and Congenital Anomalies. And Control Discorder, 2014, 2018<br>2018/04/17. doi: 10.1016/j.ajhg.2018.03.004. PubMed PMID: 29656860; PubMed Central<br>PMCID: PMCPMC5986698. 779 780 PMCID: PMCPMC5986698.<br>55. Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ, et al. De novo mutations 55. Homsy J, Zaidi S, She<br>in congenital heart disease 781 55. Montroy J, Zamery J, Sermany Marcelly Samocha Angylander Premissy Science<br>in congenital heart disease with neurodevelopmental and other congenital anomalies. Science<br>(New York, NY). 2015;350(6265):1262-6. doi: 10.1126/ 782 783 (New York, NY). 2015;350(6265):1262-6. doi: 10.1126/science.aac9396. PubMed PMID:<br>26785492. 784 ----------<br>56. Kes:<br>mutations a 785 56. Kessler MD, Loesch DP, Perry JA, Heard-Costa NL, Taliun D, Cade BE, et al. De novo mutations across 1,465 diverse genomes reveal mutational insights and reductions in the *l*<br>founder population. Proceedings of the National Academy of Sciences. 2020;117(5):25 60-9 786 787 founder population. Proceedings of the National Academy of Sciences. 2020;117(5):2560-9. doi:<br>10.1073/pnas.1902766117. 788 789 57. Nguyen TH, He X, Brown RC, Webb BT, Kendler KS, Vladimirov VI, et al. DECO: a framework for jointly analyzing de novo and rare case/control variants, and biological p<br>Brief Bioinform. 2021. Epub 2021/04/02. doi: 10.1093/bib/bbab067. PubMed PMID: 33 790 framework for jointly analyzing de novo and rare case/control variants, and biological pathways. framework for joint, analyzing de novo and rare case, control variants, and biological pathways.<br>Brief Bioinform. 2021. Epub 2021/04/02. doi: 10.1093/bib/bbab067. PubMed PMID: 33791774. 791 British British Biograph. 2021/04/02. doi: 10.1093/bib/babon. 10.1093174. PubMed PMID: 3379174. PubMed PMID: 3<br>3379174. PubMed PMID: 3379174. PubMed PMID: 3379174. PubMed PMID: 3379174. PubMed PMID: 3379174. PubMed PMID: 792